Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging

Journal of Magnetic Resonance Imaging

Volumn 31, Issue 4, 2010, Pages 796-806

  Garteiser, Philippe ^a   Doblas, Sabrina ^a   Watanabe, Yasuko ^a   Saunders, Debbie ^a   Hoyle, Jessica ^a   Lerner, Megan ^b,c   He, Ting ^a   Floyd, Robert A ^a,d   Towner, Rheal A ^a,d  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Diffusion; Glioma; MRI; OKN007; Perfusion; Treatment

Indexed keywords

(2,4 DISULFOPHENYL) N TERT BUTYLNITRONE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; OKN 007; UNCLASSIFIED DRUG; BENZENESULFONIC ACID DERIVATIVE; IMINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFLAMMATION; MORPHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BRAIN; CANCER TRANSPLANTATION; DIFFUSION; DISEASE MODEL; DRUG SCREENING; PATHOLOGY; PROCEDURES; TIME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BRAIN; CELL LINE, TUMOR; DIFFUSION; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOMA; IMINES; INFLAMMATION; MAGNETIC RESONANCE IMAGING; NEOPLASM TRANSPLANTATION; PERFUSION; RATS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950869736     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22106     Document Type: Article

References (40)

1. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999;91:1382-1390.
2. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004;70:217-228. (Pubitemid 39545733)
3. Salgaller ML, Liau LM. Current status of clinical trials for glioblastoma. Rev Recent Clin Trials 2006;1:265-281.
4. Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008;15:2887-2893.
5. Floyd RA, Kopke RD, Choi CH, Foster SB, Doblas S, Towner RA. Nitrones as therapeutics. Free Radic Biol Med 2008;45:1361-1374.
6. Kotake Y, Sang H, Miyajima T, Wallis GL. Inhibition of NF-kappaB, iNOS mRNA, COX2 mRNA, and COX catalytic activity by phenyl-N-tert-butylnitrone (PBN). Biochim Biophys Acta 1998;1448:77-84. (Pubitemid 28526622)
7. Tabatabaie T, Graham KL, Vasquez AM, Floyd RA, Kotake Y. Inhibition of the cytokine-mediated inducible nitric oxide synthase expression in rat insulinoma cells by phenyl N-tert-butylnitrone. Nitric Oxide 2000;4:157-167. (Pubitemid 30318306)
8. Blasig IE, Mertsch K, Haseloff RF. Nitronyl nitroxides, a novel group of protective agents against oxidative stress in endothelial cells forming the blood-brain barrier. Neuropharmacology 2002;43:1006-1014. (Pubitemid 35341236)
9. Endoh H, Kato N, Fujii S, et al. Spin trapping agent, phenyl Ntert-butylnitrone, reduces nitric oxide production in the rat brain during experimental meningitis. Free Radic Res 2001;35:583-591. (Pubitemid 33133594)
10. Sang H, Wallis GL, Stewart CA, Kotake Y. Expression of cytokines and activation of transcription factors in lipopolysaccharideadministered rats and their inhibition by phenyl N-tert-butylnitrone (PBN). Arch Biochem Biophys 1999;363:341-348. (Pubitemid 29394319)
11. Asanuma T, Ishibashi H, Konno A, Kon Y, Inanami O, Kuwabara M. Assessment of neuroprotective ability of a spin trap, alphaphenyl- N-tert-butylnitrone, against malonate-induced ischemic injury of rat brain by apparent water diffusion coefficient mapping. Neurosci Lett 2002;329:281-284. (Pubitemid 35245342)
12. Lyden PD, Shuaib A, Lees KR, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial. Stroke 2007;38:2262-2269. (Pubitemid 47457566)
13. Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical - trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001;32:190-198.
14. Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 2008;39:1751-1758.
15. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-571. (Pubitemid 47236281)
16. Nakae D, Kotake Y, Kishida H, et al. Inhibition by phenyl N-tertbutyl nitrone of early phase carcinogenesis in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Cancer Res 1998;58:4548-4551. (Pubitemid 28480611)
17. Inoue Y, Asanuma T, Smith N, et al. Modulation of Fas-FasL related apoptosis by PBN in the early phases of choline deficient diet-mediated hepatocarcinogenesis in rats. Free Radic Res 2007;41:972-980. (Pubitemid 47343401)
18. Doblas S, Saunders D, Kshirsagar P, et al. Phenyl-tert-butylnitrone induces tumor regression and decreases angiogenesis in a C6 rat glioma model. Free Radic Biol Med 2008;44:63-72. (Pubitemid 350138629)
19. Asanuma T, Doblas S, Tesiram YA, et al. Visualization of the protective ability of a free radical trapping compound against rat C6 and F98 gliomas with diffusion tensor fiber tractography. J Magn Reson Imaging 2008;28:574-587.
20. Sibenaller ZA, Etame AB, Ali MM, et al. Genetic characterization of commonly used glioma cell lines in the rat animal model system. Neurosurg Focus 2005;19:E1.
21. Shen G, Shen F, Shi Z, et al. Identification of cancer stem-like cells in the C6 glioma cell line and the limitation of current identification methods. In Vitro Cell Dev Biol Anim 2008;44:280-289.
22. Towner RA, Smith N, Doblas S, et al. In vivo detection of c-Met expression in a rat C6 glioma model. J Cell Mol Med 2008;12:174-186.
23. Villeneuve J, Galarneau H, Beaudet MJ, Tremblay P, Chernomoretz A, Vallieres L. Reduced glioma growth following dexamethasone or anti-angiopoietin 2 treatment. Brain Pathol 2008;18:401-414. (Pubitemid 351782849)
24. Lope-Piedrafita S, Garcia-Martin ML, Galons JP, Gillies RJ, Trouard TP. Longitudinal diffusion tensor imaging in a rat brain glioma model. NMR Biomed 2008;21:799-808.
25. Fan G, Zang P, Jing F, Wu Z, Guo Q. Usefulness of diffusion/perfusion- weighted MRI in rat gliomas: correlation with histopathology. Acad Radiol 2005;12:640-651. (Pubitemid 40603692)
26. Liimatainen T, Hakumaki JM, Kauppinen RA, Ala-Korpela M. Monitoring of gliomas in vivo by diffusion MRI and H MRS during gene therapy-induced apoptosis: interrelationships between water diffusion and mobile lipids. NMR Biomed 2009;22:272-279.
27. Zonari P, Baraldi P, Crisi G. Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging. Neuroradiology 2007;49:795-803. (Pubitemid 47497767)
28. Sun Y, Schmidt NO, Schmidt K, et al. Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med 2004;51:893-899. (Pubitemid 38580600)
29. Silva AC, Kim SG, Garwood M. Imaging blood flow in brain tumors using arterial spin labeling. Magn Reson Med 2000;44:169-173. (Pubitemid 30614774)
30. Quarles CC, Schmainda KM. Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI. Magn Reson Med 2007;57:680-687.
31. Johansson M, Bergenheim AT, Henriksson R, Koskinen LO, Vallbo C, Widmark A. Tumor blood flow and the cytotoxic effects of estramustine and its constituents in a rat glioma model. Neurosurgery 1997;41:237-243; discussion 243-244. (Pubitemid 27282098)
32. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
33. Stejskal EO, Tanner JE. Spin diffusion measurements - spin echoes in presence of a time-dependent field gradient. J Chem Phys 1965;42.
34. Herscovitch P, Raichle ME. What is the correct value for the brain - blood partition coefficient for water? J Cereb Blood Flow Metab 1985;5:65-69.
35. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res 2002;12:311-320.
36. Anda T, Yamashita H, Khalid H, et al. Effect of tumor necrosis factor-alpha on the permeability of bovine brain microvessel endothelial cell monolayers. Neurol Res 1997;19:369-376. (Pubitemid 27335144)
37. Ezhilarasan R, Mohanam I, Govindarajan K, Mohanam S. Glioma cells suppress hypoxia-induced endothelial cell apoptosis and promote the angiogenic process. Int J Oncol 2007;30:701-707.
38. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997;57:5391-5398. (Pubitemid 27516379)
39. Arrieta O, Garcia E, Guevara P, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 2002;94:3210-3218. (Pubitemid 34670504)
40. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol Res 2005;27:371-377. (Pubitemid 40734696)